Apogee's $350M offering; BiomX merges with Adaptive Phage
2024-03-06
临床1期临床2期
Plus, news about Telios Pharma and Celldex Therapeutics:
Another day, another public offering: Apogee Therapeutics is aiming to raise $350 million in a stock sale announced the same day that it shared Phase I data for its atopic dermatitis treatment in healthy volunteers that hints at potentially longer dosing intervals. — Jaimy Lee
BiomX merges with Adaptive Phage Therapeutics: The combined phage therapy biotech will have two Phase II assets: BX004 for chronic pulmonary infections in cystic fibrosis, and BX211 for diabetic foot osteomyelitis. BiomX also secured a $50 million private placement to advance the programs through clinical readouts in 2025. — Ayisha Sharma
Preview
来源: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-药物
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。